Voyager Therapeutics Inc. (VYGR)
4.27
-0.03 (-0.70%)
At close: Feb 20, 2025, 3:59 PM
4.26
-0.23%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 4.22 |
| Market Cap | 233.25M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.66 |
| PE Ratio (ttm) | 6.47 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.35 |
| Volume | 257,698 |
| Avg. Volume (20D) | 411,555 |
| Open | 4.36 |
| Previous Close | 4.30 |
| Day's Range | 4.21 - 4.37 |
| 52-Week Range | 4.00 - 10.66 |
| Beta | undefined |
About VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2015
Employees 162
Stock Exchange NASDAQ
Ticker Symbol VYGR
Analyst Forecast
According to 8 analyst ratings, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 239.58% from the latest price.
Buy 87.50%
Hold 12.50%
Sell 0.00%
Next Earnings Release
Voyager Therapeutics Inc. is scheduled to release its earnings on Mar 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+15.47%
Voyager Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
6 months ago
-14.04%
Voyager Therapeutics shares are trading lower. The company reported Q2 financial results and Wedbush lowered its price target on the stock from $8 to $7.
